CagriSema also produced significant improvements in systolic blood pressure (a 10.9 mmHg reduction), along with improvements in lipids and inflammatory markers
The evidence we do have, much of which is linked throughout this article, suggests that GLP-1 drugs alter the gut microbiome and that different strains can benefit GI symptoms
Its a leading cause of disability and a major contributor to the overall global burden of disease
ImproBiome delivers 1,957 mg of three synergistic prebiotic fibers per serving: PreticX Xylooligosaccharides (XOS), dual-source Inulin from Chicory Root and Jerusalem Artichoke, and Apple Pectin to nourish the beneficial gut bacteria responsible for natural GLP-1 production and support digestive comfort
Mechanistically, dual-pathway signaling is plausible, but strong clinical outcome data in humans are limited
Patients on insulin often need 1550% dose reductions when beginning GLP-1 therapy to avoid hypoglycemic episodes